Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canfosfamide in Refractory or Relapsed MCL, DLBCL and MM
NCT01148108Phase 2Completed
- Sponsor
- Telik, Inc.
- Start
- Jun 2010
- Primary completion
- Sep 2012
- Modality
- DNA Intercalators/Alkylators, Peptides, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of canfosfamide in mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM) (3 arms), sponsored by Telik, Inc. Primary endpoint: Objective Response Rate at 24 weeks. Started Jun 2010; status: completed.
02
Drugs
canfosfamide
03
Conditions
mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01148108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01148108.